New Capital Strengthens ProtaGene’s Advanced Analytical Leadership in the Biologics and Cell and Gene Therapy Markets November 20, 2023 By Julian Stendler
ProtaGene Appoints New Scientific and Commercial Leadership to Support Evolving Needs of Biologic and Cell and Gene Therapy Innovators January 31, 2023 By Julian Stendler
ProtaGene Names Pharmaceutical Industry Leader Raymond Kaiser as Chief Executive Officer to Drive Next Stages of Growth September 21, 2022 By Julian Stendler
FierceBio: New CRO ProtaGene to target Analytics Demand; Plans for US Testing Facility January 19, 2022 By Julian Stendler
Analytical Service Leaders in Biopharmaceutical and Gene Therapy Development Unify Operations and Re-brand as ProtaGene January 12, 2022 By Julian Stendler